Introduction: Clinicians often do not have the time and possibilities to read all scientific evidence necessary to maintain high quality patient care. They rely on guidelines made by experts to help them in their daily work. Methods: We compared the 2012 recommendations and the arguments of the IAS-USA Panel with the data referenced and presented with the original data of the studies. Special topic was the timing of antiretroviral therapy. Only studies included in the guideline text were analyzed. Results: There is a large discrepancy between the data and the recommendations concerning early antiviral therapy. The studies are either not designed to answer this question or the data is not sufficient to support the arguments. The authors highlight benefits without mention of side effects or other problems. Neither in transmission rates, nor mortality, AIDS events, comorbidities (hepatitis B and C excluded) or decreasing the risk of malignancy, the data presented support early therapy. Conclusions: A large discrepancy between the underlining data and the recommendation made by the IAS-USA Panel exists concerning early antiviral therapy.
.
Arguments of committee Comment Reference
ART reduces 96% of transmissions Absolute reduction 0.9 to 0.1 in 100 person years 82% of transmissions in Africa, and 73% of the linked transmissions in o [1] Increase of 38% of AIDS events, if started B350 B500 CD4 cells
Absolute increase of AIDS events from 1.78 to 3.63% for a time period of five years, no reduction in mortality [2] ART implementation B500 CD4 cell/uL associated with slower disease progression Absolute decrease of AIDS Events from 1.17 to 0.98/100 person years, [3] Higher CD4 cell count associated with decreased risk of AIDS and death in viral suppressed patients up to 500 CD4 cells
Absolute increase of AIDS event or death increase from 0.79 to 1.2 per 100 py [4] Lower CD4 nadir leads to poor recovery and increased morbidity and mortality
Only patients with CD4-Nadir B200/uL were included [5] 41% reduction of serious WHO stage 4 events, pulm. tuberculosis bacterial infection and death treated vs non-treated early Absolute increase from 2.4 to 3.96/100 py early vs nonearly treated
Patients with CD4 cells 500 has an identical risk of cancer compared to non-HIV Only comparison 200-499 and 500 CD4 cells, no data on patients 350-499 CD4 cells [6] Cross-section studies suggest a benefit of early ART on cardiovascular risk
Only arterial flow mediated dilatation measured. Only comparison between B350 and 350 CD4 cells. [7, 8] Renal disease increased at lower CD4 
